» Articles » PMID: 39125890

Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Aug 10
PMID 39125890
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with cystic fibrosis (CF) are prone to developing life-threatening lung infections with a variety of pathogens that are difficult to eradicate, such as , , (), , and . These infections still remain an important issue, despite the therapy for CF having considerably improved in recent years. Moreover, prolonged exposure to antibiotics in combination favors the development and spread of multi-resistant bacteria; thus, the development of alternative strategies is crucial to counter antimicrobial resistance. In this context, phage therapy, i.e., the use of phages, viruses that specifically infect bacteria, has become a promising strategy. In this review, we aim to address the current status of phage therapy in the management of multidrug-resistant infections, from compassionate use cases to ongoing clinical trials, as well as the challenges this approach presents in the particular context of CF patients.

References
1.
Rossi E, La Rosa R, Bartell J, Marvig R, Haagensen J, Sommer L . Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol. 2020; 19(5):331-342. DOI: 10.1038/s41579-020-00477-5. View

2.
Singh J, Yeoh E, Fitzgerald D, Selvadurai H . A systematic review on the use of bacteriophage in treating Staphylococcus aureus and Pseudomonas aeruginosa infections in cystic fibrosis. Paediatr Respir Rev. 2023; 48:3-9. DOI: 10.1016/j.prrv.2023.08.001. View

3.
Dedrick R, Smith B, Cristinziano M, Freeman K, Jacobs-Sera D, Belessis Y . Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clin Infect Dis. 2022; 76(1):103-112. PMC: 9825826. DOI: 10.1093/cid/ciac453. View

4.
Menon N, Penziner S, Montano E, Zurich R, Pride D, Nair B . Increased Innate Immune Susceptibility in Hyperpigmented Bacteriophage-Resistant Mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2022; 66(8):e0023922. PMC: 9380547. DOI: 10.1128/aac.00239-22. View

5.
Ashworth E, Wright R, Shears R, Wong J, Hassan A, Hall J . Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo. Nat Commun. 2024; 15(1):1547. PMC: 10879199. DOI: 10.1038/s41467-024-45785-z. View